Rich investment stock tip! Boost your money by 26%! Alkem Labs share price to soar, experts say buy
Are you an investor looking for a hot stock market tip? Well, here is a top recommendation: Alkem Lab share price is expected to go up to Rs 2,200 in the short-term while Rs 2,350 looks possible for the mid-term investment time horizon, say experts.
Are you an investor looking for a hot stock market tip? Well, here is a top recommendation: Alkem Lab share price is expected to go up to Rs 2,200 in the short-term while Rs 2,350 looks possible for the mid-term investment time horizon, say experts. Truly, if you want to become rich through share market investments, then it's important to choose the right share to buy at the right time. Stock market experts have recommended Alkem Laboratories Ltd to investors if it sustains above the crucial Rs 2,100 per stock levels. They said that Alkem Labs share price is showing upside movement and can hit Rs 2,200 to Rs 23,50 in short-term to mid-term time horizon.
Dubbing Alkem Labs as a stock worth investing in, Simi Bhaumik, a SEBI registered technical equity analyst said, "Alkem Labs share price is expected to go up to Rs 2,200 in short-term while Rs 2,350 looks possible in mid-term investment time horizon." However, she advised share market investors to buy Alkem Lab shares at around Rs 2,100 as it would pick up upside momentum once it sustains above Rs 2,100 per stock levels. "If someone takes buy position in Alkem Labs shares, he or she should strictly maintain the stop loss at Rs 2,020 to Rs 2,025 per stock levels," she said.
See Zee Business Live TV streaming below:
Recommending Alkem Labs stock to investors, Kushal Rughani, Fundamental Analyst at HDFC Securities said, "Alkem Laboratories is the prominent player in Acute therapeutic segment in India. The company is working to its strengths in the acute segment in the domestic market and is focussed on growing its presence in chronic therapies as well. It is expected that the acute season in India will be better this year, which should lead to 12-15 per cent growth in the company’s India business and around 100bps margin expansion in FY20. PAT growth is expected to be 20-25 per cent, aided by lower tax-rate. Alkem remains compliant to the US FDA, which augurs well for the US business. We are bullish on Alkem Laboratories given steady domestic acute business and gaining traction from Chronic therapeutic segment in the domestic market and double-digit growth in the US market in the next two years."
On his suggestion to the share market investors in regard to Alkem Labs stock price, Rughani said, "We expect Alkem Labs shares to hit Rs 2,650 in four quarters. Buy Alkem Labs shares with the long-term time horizon in mind."
11:56 AM IST